Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension Due to Parenchymal Lung Disease in the INCREASE Trial

Nathan, S.D.; Tapson, V.F.; Elwing, Jean M.; Rischard, Franz; Mehta, J.P.; Shapiro, S.; Shen, Eric; Edwards, Lori L.; Smith, P.; Waxman, Aaron B.

doi:10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1027

Cited by 5 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, promising results have been obtained with the use of inhaled treprostinil. A phase 3 RCT (INCREASE) examined inhaled treprostinil at a target dose of 72 µg given four times daily in 326 patients with PH associated with ILD [734,751]. The PH diagnosis was confirmed by RHC within 1 year prior to enrolment.…”

Section: Pulmonary Hypertension Associated With Interstitial Lung Dis...mentioning

confidence: 99%

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Humbert

Kovàcs²,

Hoeper³

et al. 2022

Eur Respir J

1,161

1,631

View full text Add to dashboard Cite

Section: Pulmonary Hypertension Associated With Interstitial Lung Dis...mentioning

confidence: 99%

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Humbert

Kovàcs²,

Hoeper³

et al. 2022

Eur Respir J

1,161

1,631

View full text Add to dashboard Cite

“…7 Arizona Pulmonary Specialists, Phoenix, AZ, USA. 8 Piedmont Healthcare, Atlanta, GA, USA. 9 Cedars-Sinai Medical Center, Los Angeles, CA, USA.…”

Section: Supplementmentioning

confidence: 99%

Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study

et al. 2023

View full text Add to dashboard Cite

IntroductionThe 16-week randomised, placebo-controlled INCREASE trial (RCT) met its primary endpoint by improving 6-minute walk distance (6MWD) in patients receiving inhaled treprostinil for pulmonary hypertension due to interstitial lung disease (PH-ILD). The open-label extension (OLE) evaluated long-term effects of inhaled treprostinil in PH-ILD.MethodsOf 258 eligible patients, 242 enrolled in the OLE and received inhaled treprostinil. Assessments included 6MWD, pulmonary function testing, N-terminal pro-brain natriuretic peptide (NT-proBNP), quality of life, and adverse events. Hospitalizations, exacerbations of underlying lung disease, and death were recorded.ResultsAt OLE baseline, patients had a median age of 70 years and a mean 6MWD of 274.2 m; 52.1% were male. For the overall population, the mean 6MWD at week 52 was 279.1 m and the median change from RCT baseline was 3.5 m (22.1 m for the prior inhaled treprostinil arm, −19.5 m for the prior placebo arm); the median NT-proBNP decreased from 389 pg·mL−1at RCT baseline to 359 pg·mL−1at week 64; and the absolute (% predicted) mean FVC change from RCT baseline to week 64 was 51 mL (2.8%). Patients who received inhaled treprostinilversusplacebo in the RCT had a 31% lower relative risk of exacerbation of underlying lung disease in the OLE (hazard ratio=0.69 [95% confidence interval: 0.49–0.97]; p=0.03). Adverse events leading to drug discontinuation occurred in 54 (22.3%) patients.ConclusionThese results support the long-term safety and efficacy of inhaled treprostinil in patients with PH-ILD and are consistent with the results observed in the INCREASE RCT.

show abstract

“…In another post hoc analysis of INCREASE, treatment with inhaled treprostinil resulted in decreased likelihood of disease progression defined as either ≥5% decline in 6MWD, ≥10% decline in forced vital capacity, acute exacerbation, cardiopulmonary hospitalization, lung transplantation, or death (22 versus 36% multiple progression events in treatment versus placebo groups, respectively; P =0.005). 235 The United States Food and Drug Administration approved inhaled treprostinil for Group 3 PH due to ILD on April 1, 2021, marking the first and only approved PAH therapy for Group 3 PH due to ILD in the United States.…”

Section: Pulmonary Vasodilatorsmentioning

confidence: 99%

Group 3 Pulmonary Hypertension: From Bench to Bedside

Singh

Dorfmüller

Shlobin

et al. 2022

Circulation Research

View full text Add to dashboard Cite

Pulmonary hypertension (PH) because of chronic lung disease is categorized as Group 3 PH in the most recent classification system. Prevalence of these diseases is increasing over time, creating a growing need for effective therapeutic options. Recent approval of the first pulmonary arterial hypertension therapy for the treatment of Group 3 PH related to interstitial lung disease represents an encouraging advancement. This review focuses on molecular mechanisms contributing to pulmonary vasculopathy in chronic hypoxia, the pathology and epidemiology of Group 3 PH, the right ventricular dysfunction observed in this population and clinical trial data that inform the use of pulmonary vasodilators in Group 3 PH.

show abstract

Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension Due to Parenchymal Lung Disease in the INCREASE Trial

Cited by 5 publications

References 0 publications

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study

Group 3 Pulmonary Hypertension: From Bench to Bedside

Contact Info

Product

Resources

About